These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 204615)

  • 1. Radiotherapy combined with ICRF 159 (NSC 129943).
    Rhomberg WU
    Int J Radiat Oncol Biol Phys; 1978; 4(1-2):121-6. PubMed ID: 204615
    [No Abstract]   [Full Text] [Related]  

  • 2. A clinical evaluation of ICRF 159 as a radiosensitising agent.
    Bates T
    Int J Radiat Oncol Biol Phys; 1978; 4(1-2):127-31. PubMed ID: 344288
    [No Abstract]   [Full Text] [Related]  

  • 3. Radiotherapy and ICRF 159 in the treatment of soft tissue sarcomas.
    Ryall RD
    Int J Radiat Oncol Biol Phys; 1978; 4(1-2):133-4. PubMed ID: 632140
    [No Abstract]   [Full Text] [Related]  

  • 4. [Clinical experiences with radiotherapy and ICRF 159 in sarcomas].
    Rhomberg W; Mesche E; Gefeller D; Hassenstein E
    Strahlentherapie Sonderb; 1978; 75():110-4. PubMed ID: 400195
    [No Abstract]   [Full Text] [Related]  

  • 5. Preliminary report on AT1727 as a potential radiosensitizer.
    Zhang ZY; Liu TF; Zhang XF
    Int J Radiat Oncol Biol Phys; 1984 Dec; 10(12):2305-7. PubMed ID: 6392223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of radiation and razoxane (ICRF 159) in vivo.
    Hellmann K; Grimshaw MB; Hutchinson GE
    Int J Radiat Oncol Biol Phys; 1978; 4(1-2):109-13. PubMed ID: 632139
    [No Abstract]   [Full Text] [Related]  

  • 7. Radiotherapy vs. radiotherapy and razoxane in the treatment of soft tissue sarcomas: final results of a randomized study.
    Rhomberg W; Hassenstein EO; Gefeller D
    Int J Radiat Oncol Biol Phys; 1996 Dec; 36(5):1077-84. PubMed ID: 8985029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double blind controlled clinical trial of radiation plus razoxane (ICRF 159) versus radiation plus placebo in the treatment of head and neck cancer.
    Bakowski MT; Macdonald E; Mould RF; Cawte P; Sloggem J; Barrett A; Dalley V; Newton KA; Westbury G; James SE; Hellmann K
    Int J Radiat Oncol Biol Phys; 1978; 4(1-2):115-9. PubMed ID: 344287
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of radiotherapy with and without razoxane (ICRF 159) in the treatment of soft tissue sarcomas.
    Hellmann K; Ryall RD; Macdonald E; Newton KA; James SE; Jones S
    Cancer; 1978 Jan; 41(1):100-7. PubMed ID: 414829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ICRF 159, (+/-) 1,2-di(3,5-dioxopiperazin-1-yl) propane NSC-129,943; razoxane.
    Bakowski MT
    Cancer Treat Rev; 1976 Jun; 3(2):95-107. PubMed ID: 821609
    [No Abstract]   [Full Text] [Related]  

  • 11. [Radiotherapy and ECRF 159 (NCS 129943) in the treatment of inoperable soft-tissue sarcoma (author's transl)].
    Rhomberg W; Hellmann K; Ryall RD
    Dtsch Med Wochenschr; 1974 Nov; 99(48):2438-42. PubMed ID: 4217269
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of pulmonary metastatic disease with radiation therapy and adjuvant actinomycin D. Preliminary observations.
    Cupps RE; Ahmann DL; Soule EH
    Cancer; 1969 Oct; 24(4):719-23. PubMed ID: 4309693
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase II evaluation of dibromodulcitol, ICRF-159, and maytansine for sarcomas.
    Borden EC; Ash A; Enterline HT; Rosenbaum C; Laucius JF; Paul AR; Falkson G; Lerner H
    Am J Clin Oncol; 1982 Aug; 5(4):417-20. PubMed ID: 6956236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ICRF-159: current status and clinical prospects.
    Bellet RE; Rozencweig M; Von Hoff DD; Penta JS; Wasserman TH; Muggia FM
    Eur J Cancer (1965); 1977 Nov; 13(11):1293-8. PubMed ID: 590286
    [No Abstract]   [Full Text] [Related]  

  • 15. [Radiotherapy of soft tissue tumors].
    Felci U; D'Affronto C; Fumagalli M; Gritti G; Sarti E
    Radiol Med; 1984 Nov; 70(11):891-3. PubMed ID: 6100462
    [No Abstract]   [Full Text] [Related]  

  • 16. Synovial sarcoma: an analysis of its response to radiation.
    Kagan AR; Friedman NB; Jaffe HL
    J Surg Oncol; 1971; 3(4):379-85. PubMed ID: 4329009
    [No Abstract]   [Full Text] [Related]  

  • 17. [Combined treatment of soft tissue sarcoma].
    Trishkin VA; Stoliarov VI; Frolova ZV
    Khirurgiia (Mosk); 1989 May; (5):87-91. PubMed ID: 2544767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soft-tissue sarcoma in childhood.
    Raney RB; Schnaufer L; Donaldson MH
    Semin Oncol; 1974 Mar; 1(1):57-64. PubMed ID: 4377931
    [No Abstract]   [Full Text] [Related]  

  • 19. ICRF-159 enhancement of radiation response in combined modality therapies. I. Time/dose relationships for tumour response.
    Kovacs CJ; Evans MJ; Schenken LL; Burholt DR
    Br J Cancer; 1979 May; 39(5):516-23. PubMed ID: 486307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of radiotherapy and razoxane (ICRF 159) for chondrosarcoma.
    Ryall RD; Bates T; Newton KA; Hellmann K
    Cancer; 1979 Sep; 44(3):891-5. PubMed ID: 113077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.